Cannabis Science Gets Patent for Compositions of Cannabinol to Develop Insomnia Treatment
Cannabis Science Inc, a US company specializing in the development of cannabinoid-based medicines, has received US patent number 9,763,991 for compositions of cannabinol (CBN) for treatment of various neurobehavioral disorders, sleep deprivation (insomnia), anxiety disorders (ADHD), and post-traumatic stress disorders (PTSD), among other target indications.
The invention relates to a composition for use in the treatment of neurobehavioral disorders utilizing various cannabis plant extracts comprising cannabinol (CBN) preferably with other constituents of this plant for such use and a method for the extraction of plants. The plants or plant parts may for instance be derived from cannabis sativa and/or cannabis indica and/or cannabis ruderalis and/or other elements, and mixtures thereof. The plant extracts derived showed particularly beneficial effects against sleep disorders (in particular insomnia), PTSD, and anxiety disorders including ADHD, according to the company.
This article was originally published on SleepReviewMag.com